New antibody BCD-261 put to the test in healthy volunteers
NCT ID NCT07535775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called BCD-261 in 48 healthy Chinese volunteers aged 18 to 45. The goal is to check if it is safe and how the body processes it. No treatment benefit is expected; this study is purely about safety and dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCD-261 (anti-TL1A antibody)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China